IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT04372433
Trial Phases:	Phase I	Protocol IDs:	IO-202-CL-001 (primary) NCI-2020-07121
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Immune-Onc Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT04372433

Summary

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts
of participants with AML with monocytic differentiation and CMML in order to estimate the
maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended
Phase 2 dose (RP2D)

Objectives

This is a Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety,
Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered
IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients with
Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.